Center for Health Policy

Biomedical Innovation and Evidence Development

The goal of biomedical innovation is to leverage scientific discoveries in ways that improve public health. Over the last 50 years, there has been substantial progress in the development of innovative treatments, such as vaccines to prevent measles and polio; new drugs and biologics to help manage debilitating chronic diseases, such as diabetes and heart disease; and new, effective treatments for certain types of cancer. However, millions of Americans cannot access the treatments they need because the development process is fraught with overwhelming costs, lengthy approval processes, and other regulatory challenges.

The mission of Brookings’s Biomedical Innovation and Evidence Development Program is to improve health outcomes by enhancing patient access to innovative and effective treatments and overcoming obstacles to the development and implementation of biomedical innovation. We strive to convene a diverse group of stakeholders from industry, academia, consumers, and government to ensure effective collaboration and the development of feasible policy and regulatory solutions.

FOCUS AREAS

To achieve our mission, these efforts focus on:

1. Identifying barriers to biomedical innovation and working with stakeholders to develop solutions that invigorate the creation of novel antibiotics, cancer therapies, and other devices and treatments. We also examine the role of new payment and financing strategies and opportunities to streamline the regulatory and approval processes.

2. Modernizing regulatory science to facilitate development of new methods and tools that agencies need to ensure that treatments are safe, effective, and properly monitored before they reach consumers. This includes efforts to streamline clinical trial designs, advance “personalized medicine” through the use of biomarkers and pharmacogenomics, develop measures to assess the state of quality at a drug manufacturing site, and accelerate the use of patient-reported outcomes.

3. Improving how information is gathered and shared to ensure that any safety issues are properly monitored and quickly communicated to providers and patients. This includes developing surveillance systems for drugs and medical devices in collaboration with the U.S. Food and Drug Administration and developing meaningful evidence to drive shared decision-making among patients and providers in collaboration with the Patient-Centered Outcomes Research Institute (PCORI).